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Thrombin regulates S-phase re-entry by cultured newt myotubes
Elly M. Tanaka*†, David N. Drechsel*‡ and Jeremy P. Brockes*
Background: Adult urodele amphibians such as the newt have remarkable
regenerative ability, and a critical aspect of this is the ability of differentiated cells
to re-enter the cell cycle and lose their differentiated characteristics. Unlike
mammalian myotubes, cultured newt myotubes are able to enter and traverse
S phase, following serum stimulation, by a pathway leading to phosphorylation of
the retinoblastoma protein. The extracellular regulation of this pathway is unknown.
Results: Like their mammalian counterparts, newt myotubes were refractory to
mitogenic growth factors such as the platelet-derived growth factor (PDGF),
which act on their mononucleate precursor cells. Cultured newt myotubes were
activated to enter S phase by purified thrombin in the presence of sub-
threshold amounts of serum. The activation proceeded by an indirect
mechanism in which thrombin cleaved components in serum to generate a
ligand that acted directly on the myotubes. The ligand was identified as a
second activity present in preparations of crude thrombin and that was active
after removal of all thrombin activity. It induced newt myotubes to enter S phase
in serum-free medium, and it acted on myotubes but not on the mononucleate
precursor cells. Cultured mouse myotubes were refractory to this indirect
mechanism of S-phase re-entry.
Conclusions: These results provide a link between reversal of differentiation
and the acute events of wound healing. The urodele myotube responds to a
ligand generated downstream of thrombin activation and re-enters the cell
cycle. Although this ligand can be generated in mammalian sera, the mammalian
myotube is unresponsive. These results provide a model at the cellular level for
the difference in regenerative ability between urodeles and mammals.
Background
Adult urodele amphibians such as the newt and axolotl are
capable of regenerating significant parts of the body plan
such as the limb, tail and jaw, as well as tissues such as the
lens, retina, iris and substantial sections of the heart [1,2].
A key characteristic in these various contexts is the ability
of differentiated cells to re-enter the cell cycle in response
to local injury or tissue loss, and to lose their differentiated
characteristics in a reversible fashion. For example,
removal of the lens elicits these changes in the pigmented
epithelial cells of the dorsal iris [3,4], whereas cardiac
lesions provoke extensive division of atrial and ventricular
cardiomyocytes [5,6]. Regeneration of the limb and jaw
involves the local response of mesenchymal cells to form a
growth zone or blastema underlying the wound epidermis
[7,8]. Although it is not possible to exclude some contribu-
tion from reserve cells, the widespread plasticity of differ-
entiated cells appears to be an important mechanism
underlying the difference in regenerative ability between
urodeles and other vertebrates such as mammals.
It is unclear as to what extent differentiated urodele cells
might be intrinsically different from their mammalian
counterparts in their regulation or responsiveness, and to
what extent they might be exposed to distinct extracellular
signals on initiating regeneration. We have addressed
these questions in the context of newt skeletal myotubes,
which form readily in cultures of mononucleate limb A1
cells when the serum concentration of the medium is
lowered [9–11]. When the multinucleate myotubes are
selectively labelled by microinjection of a lineage tracer
and introduced into a blastema, they give rise to labelled
mononucleate cells which divide and contribute to the
regenerate [10]. These observations have recently been
confirmed using myotubes labelled either with an inte-
grated retrovirus or with a cell-tracker dye. Furthermore,
the myotube nuclei are found to re-enter S phase after
implantation (A. Kumar, C. Velloso, Y. Imokawa and
J.P.B., unpublished observations). The behaviour of the
implanted myotubes is reminiscent of earlier observations
of endogenous muscle fibres during limb regeneration
[12,13]. These results establish that A1 myotubes are
appropriate target cells for studying the mechanisms
underlying the reversibility of differentiation.
In culture, these newt myotubes have a distinctive feature
that distinguishes them from their avian and mammalian
counterparts. A characteristic of vertebrate myogenesis is
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the entry into a stable post-mitotic arrest after fusion
[14,15]. This leaves the multinucleate myotubes com-
pletely unresponsive either to serum or to protein growth
factors which act to stimulate S-phase entry of mono-
nucleate myoblasts [16,17]. Newt myotubes maintained in
low serum media also remain stably arrested indefinitely.
When cultured newt myotubes are exposed to elevated
concentrations of serum, however, they have been
observed to traverse S phase and arrest in G2 [11]. What is
the basis for this difference between newt and mammalian
myotubes? The activity of the retinoblastoma protein (Rb)
is critical for stable withdrawal of multinucleate muscle
cells from the cell cycle. In normal mouse myotubes, the
pathway leading to cell-cycle re-entry through hyperphos-
phorylation of Rb is blocked [18], whereas in mouse
myotubes lacking both copies of the Rb gene, serum does
stimulate re-entry [19,20]. In newt A1 myotubes, the
appearance of the hyperphosphorylated, inactive form of
Rb underlies their serum response, as expression of p16,
an inhibitor of cyclin-dependent kinases (Cdks) 4 and 6,
effectively blocks S-phase re-entry [11]. These experi-
ments provide clear evidence for an intrinsic difference
between urodele and mammalian myotubes, while raising
the question as to what activity in serum might be respon-
sible for activating the Rb pathway in newt cells. 
The stimulation of S-phase entry in a cycling or quiescent
cell such as the fibroblast is a familiar aspect of the response
to serum, but the myotube is a differentiated cell, a circum-
stance which makes this example of particular interest.
Cells generally encounter serum, the soluble fraction of
clotted blood, in the context of wounding followed by
thrombin activation and haemostasis. The recent analysis of
the fibroblast response to serum, by hybridisation of RNA
to DNA microarrays, has revealed that many of the genes
that are activated are familiar players involved in wound
healing [21]. The response of urodele myotubes is thus of
additional interest because, as discussed later, wounding is
thought to be an important trigger for the responses leading
to regeneration [22]. In this paper, we have characterised
the serum activity that elicits newt myotube cell-cycle re-
entry, and report that the serum protease thrombin acts as
an indirect regulator by generating a ligand that is active on
the myotube but not on the mononucleate precursor cell.
The results provide an intriguing model for analysis at the
level of cell biology of the difference in regenerative ability
between urodeles and mammals.
Results
Responsive and refractory properties of newt and mouse
myotubes
All sources of animal sera that we tested were capable of
inducing cultured newt A1 myotubes expressing myosin
heavy chain marker to re-enter S phase; yet when, for
example, foetal bovine serum was tested in parallel on
mouse C2C12 myotubes, it was unable to induce S-phase
re-entry in these cells (Table 1). In contrast, serum was a
powerful mitogenic stimulus for the mononucleate muscle
precursors of both newt and mouse (Table 1). The ability
of serum to induce S phase in cycling and quiescent cells
usually reflects the activity of mitogenic growth factors
such as the platelet-derived growth factor (PDGF), but, in
agreement with previous results [11], a variety of mam-
malian growth factors including PDGF were found to be
inactive on A1 myotubes while stimulating the mononu-
cleate newt cells (see Table 1). This indicates first that
the post-mitotic arrest in newt myotubes — defined by
the loss of responsiveness to mitogenic factors after
fusion — is quite comparable to that in mammalian
myotubes such as C2C12 cells, and second, that the ability
of serum to countermand the post-mitotic arrest and
provoke S-phase re-entry in newt myotubes is not due to
the growth factors tested, whether singly or in a variety of
combinations (see Table 1). 
Thrombin promotes re-entry into S phase
In view of the distinctive nature of the serum activity and
its potential importance for dedifferentiation and regener-
ation, we assayed not only a variety of purified factors but
also certain crude fractions derived from plasma or serum.
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Table 1
Sensitivity of mouse C2C12 myotubes and newt A1 myotubes
to various growth factors.
Cell type PDGF* Serum†
Mouse C2C12 cells
Mononucleate + +
Myotube – –
Newt A1 cells
Mononucleate + +
Myotube – +
Myotubes were assayed for bromodeoxyuridine (BrdU) incorporation in
response to growth factors or serum. *PDGF was found to be active
on newt A1 mononucleate cells but inactive on newt myotubes. Other
growth factors with the same properties include: basic fibroblast
growth factor (bFGF, 10 ng/ml); keratinocyte growth factor
(10–50 ng/ml); epidermal growth factor (EGF, 50 ng/ml); and insulin-
like growth factor-1 (IGF-1; 100 ng/ml). The following growth factors
and other substances were assayed solely on myotubes and found to
be inactive: tumour necrosis factor α (TNF-α, 2000 U/ml); activin A
(10–20 ng/ml); macrophage stimulating protein (3–30 nM);
hepatocyte growth factor (2–10 U/ml); murine colony stimulating
factor (mCSF, 5 U/ml); glial growth factor (10–20 ng/ml); retinoic acid
(0.1–1.0 nM); lysophosphatidic acid (2–20 ng/ml); sonic hedgehog
(0.4–40 µg/ml); thrombin-receptor agonist peptide (1–100 nM ); and
platelet lysate. Transforming growth factor β (TGF-β, 200 U/ml) was
inactive on myotubes and induced cell-cycle arrest in mononucleate
cells. †Serum sources tested (in addition to foetal bovine serum) and
found to be active include adult bovine, sheep, porcine and chicken
sera. We were unable to obtain sufficient quantities of urodele sera for
assay. In assays on mononucleate A1 cells, a plus sign represents a
greater than fivefold increase in the number of BrdU-positive cells
compared with media containing 1% serum. In assays on myotubes, a
minus sign means less than 5% BrdU-positive cells in an assay in
which serum induced 30% BrdU-positive cells. 
For example, platelet lysate, a potent source of activities
on cycling and quiescent cells, was tested but found to
have no detectable ‘re-entry activity’ on A1 myotubes.
One plasma derivative, however, contained significant
S-phase re-entry activity. Commercial preparations of
crude thrombin, prepared from bovine plasma, were found
to be active on newt myotubes in the concentration range
10–100 µg/ml, whereas foetal bovine serum was active at
1–5 mg/ml (Figure 1a). When crude thrombin was frac-
tionated by adsorption to and elution from an anion
exchange resin, Q–sepharose, two peaks of activity were
obtained (Figure 1b). Peak I, which eluted at 200 mM
NaCl, was further chromatographed on a cation exchange
resin, SP–sepharose, and eluted at 500 mM NaCl as a
single peak of activity co-incident with the major peak of
protein (Figure 1c). After SDS gel electrophoresis and
western blotting this was found to contain highly purified
thrombin (Figure 1).
The dependence of S-phase re-entry on thrombin activity
was established using a panel of protease inhibitors. Prote-
olytic activity was removed by prior treatment of the
SP–sepharose fraction with either of two protein inhibitors
— anti-thrombin III (ATIII), which acts at the active site of
several serine proteases [23], and hirudin, which acts at the
fibrinogen-binding exosite of thrombin [24] (Figure 1d). A
small-molecule inhibitor, PPACK, which alkylates the his-
tidine residue of the catalytic centre [25], also completely
removed proteolytic activity at a concentration of 10 µM
(data not shown). All of these inhibitor-treated samples had
no significant residual activity on the newt myotubes.
Thrombin-mediated re-entry requires serum
An important aspect of the action of thrombin on newt
myotubes is illustrated in Figure 2. When myotubes were
cultured under conditions in which serum was replaced
with 1% crystalline bovine serum albumin (BSA), the
myotubes were refractory to thrombin stimulation,
whereas thrombin strongly stimulated re-entry in the pres-
ence of sub-threshold concentrations of serum. In control
experiments, myotubes cultured under serum-free condi-
tions were found to be fully responsive to serum stimula-
tion, and, as shown later, to partially purified protein
fractions. Thrombin could either be acting directly on the
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Figure 1
Identification of bovine thrombin as a protein
that elicits newt myotube cell cycle re-entry.
(a) Myotube S-phase re-entry activity of a
crude bovine thrombin preparation compared
with foetal bovine serum (FBS). Activity was
assayed as the percentage of myotubes that
were BrdU-positive. (b) The re-entry activity
in crude bovine thrombin fractionated as two
distinct peaks, I and II. Crude bovine
thrombin (7 mg, Calbiochem) was applied to
a 1 ml HiTrap Q–sepharose column
(Pharmacia) in 20 mM Tris–HCl, pH 8.0 and
eluted with a linear 0 to 0.7 M NaCl gradient
(upper dashed line) followed by a 1 M NaCl
wash. Continuous line, protein profile
(OD280); closed squares with dashed line,
activity profile quantitated as percentage of
myotubes that were BrdU-positive. Peak I
eluted at 200 mM NaCl, peak II at 440 mM
NaCl. (c) The activity in peak I co-
fractionated with thrombin. Peak I fractions
from Q–sepharose were pooled, applied to a
1 ml HiTrap SP–sepharose column in 20 mM
HEPES pH 7.5, 100 mM NaCl and eluted
with a linear 0.1 to 0.7 M salt gradient (upper
dashed line). The protein profile (continuous
line) shows one major peak eluting at
500 mM NaCl. The activity profile (closed
squares with dashed line) coincides with this
peak. The pooled fractions of the major peak
contained 280 µg/ml protein. *A silver-
stained gel of the peak fraction following
SDS–PAGE (12%) showed that it contained
only the α, β and γ forms of thrombin (this
was confirmed by western blot analysis using
polyclonal antibodies to thrombin; data not
shown). (d) Inhibition of thrombin proteolytic
activity in the fraction eluted from
SP–sepharose abolished its activity on
myotubes. The SP–sepharose fraction was
assayed at 19 µg/ml, and thrombin was
present at approximately 0.5 µM. ATIII or
hirudin was added to SP–sepharose
fractions in a 2:1 or 5:1 molar excess,
respectively, before assaying on myotubes.
Control, SP–sepharose fraction with no
inhibitor added.
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myotubes by amino-terminal cleavage and activation of its
membrane receptor [26,27], or indirectly by cleavage of
molecules in serum leading to activation or generation of a
ligand which then acts directly on the myotubes through a
pathway unrelated to the thrombin receptor. The newt
myotubes were unresponsive to the thrombin-receptor
agonist peptide (Table 1, legend), but more conclusive
evidence for the second, indirect model has come from
the use of thrombin inhibitors.
Thrombin generates re-entry activity in serum
Medium containing a sub-threshold amount of serum was
pre-incubated with thrombin for 24 hours, before addition
of sufficient hirudin or PPACK to inactivate protease
activity (Figure 3a and see Materials and methods). The
resulting medium was added to the newt myotubes in a
standard assay. The thrombin pre-incubation generated
significant re-entry activity, up to a thirtyfold increase over
the basal level in the medium, and this was dependent on
the thrombin concentration (Figure 3b). In control experi-
ments, thrombin and its inhibitor were added together at
the beginning of the preincubation, and this generated no
significant re-entry activity (Figure 3b).
A variety of proteases were tested in this serum-generation
assay (Figure 3, legend), but these were inactive with one
exception. When plasmin was incubated as shown in
Figure 3a and then inactivated with α2-antiplasmin, it
generated significant activity on the newt myotubes, and
this activity was not detected when the inhibitor and pro-
tease were added simultaneously (Figure 3c). Thus, the
two coagulation-related proteases were able to generate re-
entry activity from components in serum.
Thrombin activity is elevated in the limb blastema
To evaluate the possible significance of this indirect
mechanism for inducing cell-cycle re-entry during regen-
eration, we assayed thrombin activity in the blastema with
an overlay method which permits tissue-level resolution
[28]. Newt limbs undergoing regeneration were sectioned
in a cryostat 8 days after amputation, a stage when the
blastema is forming by reversal of differentiation in the
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Figure 2
Pure thrombin required the presence of serum to elicit cell-cycle
re-entry. Thrombin (0.23 µM) was assayed on newt myotubes under
serum-free (1% bovine serum albumin; BSA) conditions or in the
presence of 1.5% foetal bovine serum. Thrombin elicited no response
in serum-free conditions but had potent activity in 1.5% serum. 
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Figure 3
Thrombin- and plasmin-dependent proteolysis can generate S-phase
re-entry activity from serum. (a) Medium containing 1.5% foetal bovine
serum (which does not induce S-phase re-entry) was incubated with
thrombin or plasmin for 24 h at room temperature before protease
inhibitor treatment (hirudin or α2-antiplasmin) as described in the
Materials and methods. This preparation was added to newt myotubes,
which were then assayed for BrdU incorporation by a standard assay
procedure and then fixed. In control experiments, protease and
inhibitor were added simultaneously. The proteolytic activity in samples
was monitored at 0 and 24 h (asterisks) using the chromogenic
substrates tosyl-glycyl-prolyl-arginine-4-nitranilide acetate
(ChromozymTH, Boehringer) for thrombin and tosyl-glycyl-prolyl-lysine-
4-nitranilide acetate (ChromozymPL, Boehringer) for plasmin (see
Materials and methods). (b) Thrombin-dependent generation of activity
from 1.5% serum. Filled diamonds, samples incubated with thrombin
for 24 h before protease inhibitor treatment; open squares, samples in
which thrombin and hirudin were added simultaneously. Similar results
were obtained using PPACK as inhibitor. (c) Plasmin-dependent
generation of activity from 1.5% foetal bovine serum. Filled diamonds,
samples incubated with plasmin for 24 h before protease inhibitor
treatment; open squares, samples in which plasmin and α2-antiplasmin
were added simultaneously. Although plasmin activity was largely
neutralised by serum, α2-antiplasmin was used to inhibit any residual
proteolytic activity. Other proteases that were tested in this assay and
found to be negative included trypsin, Factor Xa, Protein Ca, Factor IX
and Factor XII.
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mesenchymal tissue at the end of the stump. The sections
were overlaid with a membrane impregnated with a fluoro-
genic thrombin substrate — a coumarin ester of D-Phe-
Pro-Arg (see Materials and methods). This resulted in
selective generation of fluorescent reaction product in the
mesenchyme at the end of the limb underneath the
wound epidermis (Figure 4a,b, asterisks). The signal was
completely inhibited by inclusion of PPACK (Figure 4c,d).
It is interesting that thrombin activity is locally high in this
region at a time significantly later than the acute events of
clotting, which occur immediately after amputation. As
this mechanism might operate during limb regeneration,
and during local wounding (see Discussion), it was impor-
tant to study the ligand that is generated downstream of
thrombin activation, and that acts directly on the myotube.
Identification of a second re-entry activity 
We analysed the second activity detected in crude throm-
bin preparations (Figure 1b), which appeared to have the
properties expected of the ligand in question. When peak
I, previously identified as thrombin (Figure 1c,d), was
assayed in the presence and absence of serum, it was found
to be completely serum dependent (Figure 5a) as observed
for purified thrombin (Figure 2). In contrast, peak II,
which eluted from Q–sepharose at 440 mM NaCl, retained
approximately 40% of its activity on myotubes under
serum-free conditions (Figure 5a). Preparations treated
with PPACK to remove all traces of thrombin activity also
retained significant activity in serum-free media.
A notable feature of peak II is its profile of activity on
mononucleate cells versus myotubes (Figure 5b). Whereas
foetal bovine serum and crude thrombin were active, as
expected, on both myotubes and mononucleate cells, the
activities in peaks I and II had little or no effect on mononu-
cleate cells. The activity on mononucleate cells, which is
present in the crude thrombin preparation, is a distinct com-
ponent which flows through the Q–sepharose column and
has a specificity resembling mitogenic growth factors (see
Table 1) in that it acts on the precursors but not on the dif-
ferentiated myotubes. Thus, the activity in peak II
796 Current Biology, Vol 9 No 15
Figure 4
Thrombin proteolytic activity is elevated in the zone of
de-differentiation. Thrombin proteolytic activity was localised in
sections of regenerating newt limbs using a membrane overlay
procedure. (a,c) Membrane overlay assay on a section through a day 8
regenerate in the (a) absence or (c) presence of the thrombin inhibitor
PPACK. In (a), there is a strong fluorescent reaction product in the
mesenchymal tissue at the end of the stump. No fluorescent signal is
detectable in (c). (b,d) Propidium iodide staining of the identical
sections shown in (a,c), respectively, to show nuclei within the
regenerate. The scalebar represents 1 mm.
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Figure 5
Evidence that the Q–sepharose peak II (see Figure 1) contains the
activity generated downstream of thrombin that acts directly on
myotubes. (a) Activity of peaks I and II on myotubes cultured in low
serum (0.5%) or serum-free (1% crystallised BSA) conditions. Peak I
was assayed at 50 µg/ml, and peak II at 1 mg/ml protein concentration.
Higher concentrations of peak I resulted in lower cell responses or cell
detachment. Peak I, which contains purified thrombin, was active in
low-serum conditions but not in serum-free conditions whereas peak II
was active under both low-serum and serum-free conditions.
(b) Activity of Q–sepharose peaks on myotubes versus mononucleate
precursors. Samples from the peak fractions were added to myotubes
in low-serum media, or, in parallel, to mononucleate cells that had been
serum starved for 24 h and maintained in serum-free media. Although
the crude thrombin preparation stimulated cell-cycle re-entry in both
the myotubes and mononucleate cells, the chromatographic properties
of the activities were distinct. The mitogenic activity for mononucleate
cells was found in the Q–sepharose flow-through fraction, whereas
peaks I and II had very low levels of such activity. In contrast, the
activity that stimulates the newt myotubes was absent in the flow-
through fraction, but high in peaks I and II. The following
concentrations were employed for these assays: foetal bovine serum
(9 mg/ml), crude thrombin (69 µg/ml), Q–sepharose flow-through
(< 50 µg/ml), peak I (40 µg/ml), peak II (0.78 mg/ml).
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appeared to act specifically on myotube S-phase re-entry.
Thrombin-treated serum preparations (as in Figure 3b) also
showed the same selective activity on myotubes but not on
mononucleate cells (data not shown). Although firm conclu-
sions must await the purification and identification of the
activity in peak II, it is also notable that this activity has the
same elution profile after gel filtration on Superose 12 as the
activity in serum (Mr = 2.5 × 105).
Discussion
In earlier work, we found that phosphorylation of Rb, an
intracellular regulator of the cell cycle, appeared to be
necessary to induce S-phase re-entry by newt myotubes
[11]. The present results indicate that this pathway is ini-
tiated by the generation of a distinct extracellular activity.
The appearance of this activity in vitro could be regulated
by thrombin-mediated proteolysis, and also by plasmin,
whereas various other proteases were negative in this
assay. It is unclear whether the mechanism by which this
activity is generated involves direct cleavage of a precur-
sor form, cleavage and inactivation of an inhibitor, or initi-
ation of a more complex cascade. Nonetheless, our results
provide a connection between plasticity of the differen-
tiated state and the acute events of injury, wound healing
and haemostasis [29,30]. In this context, it is interesting
that thrombin activity was found to be elevated in the
mesenchymal tissue at the end of the limb stump, at a
stage when both implanted A1 myotubes and endogenous
myofibres have been observed to enter S phase
(A. Kumar, C. Velloso, Y. Imokawa and J.P.B., unpub-
lished observations). 
It has long been recognised that local wounding of the
urodele limb or flank evokes the appearance of various
markers characteristic of blastemal cells [31], including
two members of the HoxD complex [32]; furthermore, if a
major peripheral nerve is transected and inserted into such
a wound so as to stimulate division, then a supernumerary
limb may form [33]. We suggest that local activation of
thrombin may be an important signal for cell-cycle
re-entry by differentiated cells through the indirect mech-
anism identified here (see Figure 6 for summary). It is
obviously important that de-differentiation remains
localised to the zone at the end of the stump, just as it is
critical that formation of a clot does not propagate from the
site of injury [29]. Therefore, the mechanisms that localise
and inactivate thrombin in the latter case may also be rele-
vant to the former.
The identity of the ligand that is generated as a down-
stream product of thrombin action is currently not known.
It clearly does not involve further thrombin activity, and
can be separated from inactivated thrombin by subsequent
chromatography. It is unlikely to involve further protease
activity given that it is resistant to broad spectrum serine-
protease inhibitors. The identification of angiogenic and
anti-angiogenic activity in fragments of fibrin, collagen
XVIII and plasminogen raises the possibility that other
Figure 6
Schematic diagram of the activation of
S-phase re-entry by newt myotubes in the
context of the wound-healing responses that
lead to regeneration. Amputation of the limb
triggers multiple responses such as
inflammation and cell migration. A major
aspect of wound healing is activation of the
coagulation cascade, resulting in the
conversion of prothrombin to thrombin. In
mammals, this induces the conversion of
fibrinogen to fibrin polymers and formation of
a clot. In newts, thrombin activation, in
addition, leads to cell-cycle re-entry from the
differentiated state. This involves the
conversion of a latent activity (F to Fa) within
serum which can selectively stimulate newt
myotubes, but not their mononucleate
precursors, to undergo S phase. Although the
Fa activity was found in all animal sera tested,
and hence is likely to be a general product of
thrombin activation, mouse C2C12 myotubes
were refractory to this activity.
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products of proteolysis may carry biological activity [34–36].
We have investigated several substrates of thrombin in
serum, including protein C, fibrinogen/fibrin, apolipopro-
tein E and thrombospondin, but none have led to activity
on newt myotubes. Although characterisation of the active
species will require significant further purification, the
activity as identified has several interesting properties. Not
only does it act, unlike thrombin, in serum-free medium,
but it also shows specificity for the myotube as distinct
from mononucleate cells — the opposite distinction to that
made by mitogenic growth factors such as PDGF. It is
likely, therefore, that responsiveness is a specific property
of the differentiated state; it is clear that the division of
mononucleate blastemal cells, once they are generated, is
regulated by quite different mechanisms involving local
positional disparity as well as the nerve supply [7,37,38]. 
Finally, our results emphasise the importance for regener-
ation of the difference in responsiveness between newt
myotubes and their mammalian counterparts, rather than
the existence of any urodele-specific signal. The activity
referred to as Fa (Figure 6) was detected in all sources of
serum that we have analysed, and its generation in verte-
brates may be a universal feature of the downstream
events following wounding and thrombin activation. In
this view the regenerative ability of the newt depends crit-
ically on the responsiveness of its differentiated cells, as
exemplified here by the cultured and implanted myotube.
The characterisation of Fa should allow an analysis of the
pathway leading to phosphorylation of Rb in the myotube,
and eventually to an understanding of why it does not
operate in the mammalian myotube, and whether it oper-
ates in any other mammalian cells.
Materials and methods
Cell culture and myotube purification
Newt A1 cells were cultured essentially as described [9,11]. Cells
were grown on gelatin-coated plastic in 65% Eagles MEM, 10% heat-
inactivated foetal bovine serum, 25% H2O, 10 µg/ml insulin and peni-
cillin/streptomycin. For myotube purification, two plates of cells, each
containing 8 × 105 cells in medium containing 0.5% serum (low-serum
medium), were cultured for 4 days to induce myogenic differentiation.
The cells were then trypsinised, neutralised in 0.5% serum-containing
medium, filtered through 100 µm meshes (Cell MicroSieve, BioDesing
Inc.) and the filtrate passed through 35 µm meshes. The myotubes
retained on the 35 µm meshes were washed into low-serum medium
and plated into a gelatin-coated 96-well plate (150 µl/well).
Substances such as growth factors were added 24 h after plating and
samples were always assayed in triplicate and the results averaged.
Unless otherwise specified, cells were routinely assayed in the pres-
ence of 1.5% foetal bovine serum, which gave a response of < 1.5%
BrdU-positive myotubes in an assay for which the maximal response
was always at least 35% BrdU-positive myotubes. For the serum-free
assays, myotubes were purified and plated in media with serum substi-
tuted by 1% BSA (final), and assayed. BrdU was added at 10 µg/ml on
day 4 for 18 h. Cells were fixed briefly in 2% paraformaldehyde and
rinsed twice in 0.1% BSA/PBS before post-fixing with methanol. Cells
were stained for BrdU as described previously [11] using a double
layer of secondary antibodies: rhodamine-conjugated rabbit anti-mouse
IgG, and then rhodamine-conjugated swine anti-rabbit IgG (Dakopatts).
Myotubes were then stained directly for muscle-specific myosin heavy
chain using monoclonal mouse IgG A4.1025 (a kind gift of S. Hughes)
which had been coupled to Fluorescein-NHS (Molecular Probes). 
C2C12 cells were propagated essentially as described [11]. They were
grown in 15% foetal bovine serum in DMEM with 10 µg/ml insulin.
Myotube differentiation in a confluent 10 cm plate was induced by
switching to medium containing 2% horse serum. C2C12 myotubes
were purified as described above for newt A1 moytubes except cells
were passed through the 35 µm mesh and trapped onto a 15 µm mesh. 
Growth factors
The following kindly provided growth factors: Ontogeny (sonic hedge-
hog), C. Heldin (platelet lysate), C. Hill (activin A), E.J. Leonard (MSP),
A. Ridley (HGF), L. Cheng and A. Mudge (GGF), and M. Noble (bFGF,
EGF, IGF-1). KGF and TNF-α were from R+D laboratories; and retinoic
acid, lysophosphatidic acid and thrombin-receptor agonist peptide
were from Sigma; mCSF and TGF-β2 were from Genzyme.
Protease treatment of serum
All purified proteases and bovine antithrombin III were purchased from
Enzyme Research Laboratories except trypsin, which was purchased
from GIBCO. Hirudin and D-Phe-Pro-Arg chloromethyl ketone (PPACK)
were purchased from Calbiochem, and α2-antiplasmin was from Sigma.
For generation of activity in serum by thrombin or plasmin, 1.5% serum-
containing medium was incubated with thrombin (0.23–0.92 µM ) or
plasmin (0.09–0.53 µM) for 24 h at 25°C in 2% CO2. Proteolytic activ-
ity in samples was monitored just after addition and at 24 h using the
chromogenic substrates tosyl-glycl-prolyl-arginine-4-nitranilide acetate
(ChromozymTH, Boehringer) for thrombin, and tosyl-glycyl-prolyl-lysine-
4-nitranilide acetate (ChromozymPL, Boehringer) for plasmin. Samples
were monitored at 405 nm every 20 s for at least 3 min to determine
activity. In uninhibited samples, approximately 70% of the thrombin
activity remained, whereas, at most, 50% of plasmin activity remained
after 24 h. To inhibit the remaining proteolytic activity, hirudin was
added at a 5:1 molar excess in thrombin experiments, and α2-antiplas-
min at a 2:1 molar excess in plasmin experiments. This resulted in most
cases in undetectable levels of activity, and in all cases proteolytic
activity was inhibited to at least fourfold less than the levels required to
elicit any BrdU uptake in myotubes; 100 µl of inhibitor-treated sample
was then added to each well for assay.
Fractionation of crude thrombin
Q–sepharose fractionation of crude thrombin (Figure 1b) was per-
formed using FPLC (Pharmacia). Crude thrombin (0.8 ml, 7 mg/ml,
800 NIH units; Calbiochem) was loaded onto a 1 ml HiTrap Q column
(Pharmacia) in 20 mM Tris-HCl pH 8.0 at a flow rate of 1 ml/min. Non-
adherent protein was washed in five column volumes and proteins
were eluted with a 0–700 mM NaCl gradient over 10 column volumes.
Fractions of 1.25 ml were collected and 1 ml of each was desalted into
serum-free cell culture medium using NAP-10 columns (Pharmacia).
Protein was monitored by absorbance at 280 nm and in pooled frac-
tions using BCA protein determination reagent (Pierce).
For purification of thrombin (Figure 1c), 0.8 ml crude thrombin (7 mg/ml,
800 NIH units; Calbiochem) was loaded onto a 1 ml HiTrap Q column
(Pharmacia) in 20 mM Tris-HCl, 100 mM NaCl pH 8.0 at 1 ml/min. Under
these conditions, peak I (containing thrombin) was not retained on the
column and flowed through. Non-adherent protein was washed in five
column volumes and proteins were eluted with a 100–600 mM NaCl gra-
dient over 10 column volumes. The flow-through fraction (containing peak
I) from the HiTrap Q column was pooled and 2.5 ml was desalted into
20 mM HEPES pH 7.5, 100 mM NaCl on a PD10 column (Pharmacia);
3.5 ml of the desalted material was loaded onto a 1 ml HiTrap SP column
(Pharmacia) in 20 mM HEPES pH 7.5, 100 mM NaCl at 1 ml/min. Non-
adherent protein was washed in five column volumes and proteins were
eluted with a 0–700 mM NaCl gradient over ten column volumes. Frac-
tions (1.25 ml) were collected and 1 ml of each was desalted into newt
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serum-free cell culture medium using NAP-10 columns (Pharmacia). The
major peak eluted at 500 mM NaCl (Figure 1c).
All chromatographic fractions and pools were assayed at three or more
protein levels covering a 20-fold range in concentration. Pools from
Q–sepharose fractionation shown in Figure 5 have the following protein
concentrations: Figure 5a — peak I, 0.37 mg/ml; peak II, 1.5 mg/ml;
Figure 5b — foetal calf serum, 60 mg/ml; crude thrombin 6.9 mg/ml;
flow-through, < 50 µg/ml; peak I, 0.3 mg/ml; peak II, 1.2 mg/ml.
Membrane overlay assays for thrombin
Localisation of thrombin activity in limb sections was performed as
described [28]. Newt limbs at 8–15 days post-amputation were fast
frozen on dry ice in Tissuetek (Sakura Finetek) and 10 µm sections were
prepared, collected on silane-coated slides and stored at –80°C.
Samples were air-dried at room temperature for 30 min, fixed in methanol,
rehydrated in TBS, stained in 10 µm propidium iodide and then placed in
TBS + 100 µg/ml BSA. Thrombin substrate membranes impregnated
with 7-amino-4-trifluoromethyl coumarin-D-Phe-Pro-Arg (AFC-64, Enzyme
System Products), were briefly hydrated in water, then TBS and placed
immediately onto the sections. Excess liquid was removed and coverslips
sealed in place with nail varnish. Images were collected between 1 and
5 hours later on a Zeiss Axiophot with a cooled CCD camera, and with
computer software from Image Pro Plus (Photonic Science). Control sec-
tions were incubated with 1 µM PPACK before exposure to membrane.
Images of control and experimental samples were collected under identi-
cal conditions. Nuclei within the sections were visualised under fluores-
cence optics after staining with propidium iodide.
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